secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-07-28T23:59:59+00:00
Accession:  0001641172-25-021105
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotech gets FDA Fast Track for ateganosine in NSCLC; Phase 2 data shows 17.8-month median OS
--------------------------------------------------------------------------------

- FDA granted Fast Track designation for ateganosine (THIO) for treatment of non-small cell lung cancer.
- Phase 2 THIO-101 trial showed median overall survival of 17.8 months in heavily pre-treated patients, vs. 5-6 months for standard of care.
- Ateganosine is a first-in-class small molecule telomere-targeting agent; if approved, could compete in $34B NSCLC market.
- Fast Track enables accelerated approval and priority review; FDA decision possible as early as next year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225021105/0001641172-25-021105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225021105/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-021105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer